Left frontal lobe hypoperfusion and depressive symptoms in Alzheimer's disease patients taking cholinesterase inhibitors

Etsuko Oshima, Seishi Terada, Shuhei Sato, Chikako Ikeda, Kouji Oda, Shinichiro Inoue, Kiyohiro Kawada, Osamu Yokota, Yosuke Uchitomi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Depressive symptoms are common in patients with Alzheimer's disease (AD) and increase the caregiver burden. Many studies have reported dorsolateral prefrontal hypometabolism or hypoperfusion in AD patients with depressive symptoms, most of whom did not take acetylcholinesterase inhibitors (AChEI). It is not clear, however, whether a similar condition is present in patients taking AChEI medication. Fifty-seven consecutive AD patients taking AChEI were recruited at a memory clinic. Objective depressive symptoms were evaluated using the depression domain of the Neuropsychiatric Inventory (NPI-dep). All patients underwent brain single photon emission computed tomography (SPECT) with (99m)Tc-ethylcysteinate dimer, and the SPECT images were analyzed using the Statistical Parametric Mapping 8 program. No significant differences between groups with positive and negative NPI-dep scores were found with respect to age, sex, years of education, and cognitive function. Compared with patients with negative NPI-dep scores, patients with NPI-dep scores ≥1 showed significant hypoperfusion in the left middle frontal region. Our results indicate that the dorsolateral prefrontal area is significantly involved in the pathogenesis of depressive symptoms in AD patients being treated with AChEI. The area on the left side especially may be closely related to the depressive symptoms evaluated using the NPI.

Original languageEnglish
Pages (from-to)319-323
Number of pages5
JournalPsychiatry Research
Volume224
Issue number3
DOIs
Publication statusPublished - Dec 30 2014

Fingerprint

Cholinesterase Inhibitors
Frontal Lobe
Alzheimer Disease
Depression
Single-Photon Emission-Computed Tomography
Sex Education
Cognition
Caregivers
Equipment and Supplies
Brain

Keywords

  • Acetylcholine esterase inhibitor (AChEI)
  • Alzheimer׳s disease
  • Depression
  • Neuropsychiatric inventory (NPI)
  • Regional cerebral blood flow (rCBF)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Left frontal lobe hypoperfusion and depressive symptoms in Alzheimer's disease patients taking cholinesterase inhibitors. / Oshima, Etsuko; Terada, Seishi; Sato, Shuhei; Ikeda, Chikako; Oda, Kouji; Inoue, Shinichiro; Kawada, Kiyohiro; Yokota, Osamu; Uchitomi, Yosuke.

In: Psychiatry Research, Vol. 224, No. 3, 30.12.2014, p. 319-323.

Research output: Contribution to journalArticle

Oshima, Etsuko ; Terada, Seishi ; Sato, Shuhei ; Ikeda, Chikako ; Oda, Kouji ; Inoue, Shinichiro ; Kawada, Kiyohiro ; Yokota, Osamu ; Uchitomi, Yosuke. / Left frontal lobe hypoperfusion and depressive symptoms in Alzheimer's disease patients taking cholinesterase inhibitors. In: Psychiatry Research. 2014 ; Vol. 224, No. 3. pp. 319-323.
@article{9ab38322b0a84f998deea66f5c89d6b5,
title = "Left frontal lobe hypoperfusion and depressive symptoms in Alzheimer's disease patients taking cholinesterase inhibitors",
abstract = "Depressive symptoms are common in patients with Alzheimer's disease (AD) and increase the caregiver burden. Many studies have reported dorsolateral prefrontal hypometabolism or hypoperfusion in AD patients with depressive symptoms, most of whom did not take acetylcholinesterase inhibitors (AChEI). It is not clear, however, whether a similar condition is present in patients taking AChEI medication. Fifty-seven consecutive AD patients taking AChEI were recruited at a memory clinic. Objective depressive symptoms were evaluated using the depression domain of the Neuropsychiatric Inventory (NPI-dep). All patients underwent brain single photon emission computed tomography (SPECT) with (99m)Tc-ethylcysteinate dimer, and the SPECT images were analyzed using the Statistical Parametric Mapping 8 program. No significant differences between groups with positive and negative NPI-dep scores were found with respect to age, sex, years of education, and cognitive function. Compared with patients with negative NPI-dep scores, patients with NPI-dep scores ≥1 showed significant hypoperfusion in the left middle frontal region. Our results indicate that the dorsolateral prefrontal area is significantly involved in the pathogenesis of depressive symptoms in AD patients being treated with AChEI. The area on the left side especially may be closely related to the depressive symptoms evaluated using the NPI.",
keywords = "Acetylcholine esterase inhibitor (AChEI), Alzheimer׳s disease, Depression, Neuropsychiatric inventory (NPI), Regional cerebral blood flow (rCBF)",
author = "Etsuko Oshima and Seishi Terada and Shuhei Sato and Chikako Ikeda and Kouji Oda and Shinichiro Inoue and Kiyohiro Kawada and Osamu Yokota and Yosuke Uchitomi",
year = "2014",
month = "12",
day = "30",
doi = "10.1016/j.pscychresns.2014.10.008",
language = "English",
volume = "224",
pages = "319--323",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Left frontal lobe hypoperfusion and depressive symptoms in Alzheimer's disease patients taking cholinesterase inhibitors

AU - Oshima, Etsuko

AU - Terada, Seishi

AU - Sato, Shuhei

AU - Ikeda, Chikako

AU - Oda, Kouji

AU - Inoue, Shinichiro

AU - Kawada, Kiyohiro

AU - Yokota, Osamu

AU - Uchitomi, Yosuke

PY - 2014/12/30

Y1 - 2014/12/30

N2 - Depressive symptoms are common in patients with Alzheimer's disease (AD) and increase the caregiver burden. Many studies have reported dorsolateral prefrontal hypometabolism or hypoperfusion in AD patients with depressive symptoms, most of whom did not take acetylcholinesterase inhibitors (AChEI). It is not clear, however, whether a similar condition is present in patients taking AChEI medication. Fifty-seven consecutive AD patients taking AChEI were recruited at a memory clinic. Objective depressive symptoms were evaluated using the depression domain of the Neuropsychiatric Inventory (NPI-dep). All patients underwent brain single photon emission computed tomography (SPECT) with (99m)Tc-ethylcysteinate dimer, and the SPECT images were analyzed using the Statistical Parametric Mapping 8 program. No significant differences between groups with positive and negative NPI-dep scores were found with respect to age, sex, years of education, and cognitive function. Compared with patients with negative NPI-dep scores, patients with NPI-dep scores ≥1 showed significant hypoperfusion in the left middle frontal region. Our results indicate that the dorsolateral prefrontal area is significantly involved in the pathogenesis of depressive symptoms in AD patients being treated with AChEI. The area on the left side especially may be closely related to the depressive symptoms evaluated using the NPI.

AB - Depressive symptoms are common in patients with Alzheimer's disease (AD) and increase the caregiver burden. Many studies have reported dorsolateral prefrontal hypometabolism or hypoperfusion in AD patients with depressive symptoms, most of whom did not take acetylcholinesterase inhibitors (AChEI). It is not clear, however, whether a similar condition is present in patients taking AChEI medication. Fifty-seven consecutive AD patients taking AChEI were recruited at a memory clinic. Objective depressive symptoms were evaluated using the depression domain of the Neuropsychiatric Inventory (NPI-dep). All patients underwent brain single photon emission computed tomography (SPECT) with (99m)Tc-ethylcysteinate dimer, and the SPECT images were analyzed using the Statistical Parametric Mapping 8 program. No significant differences between groups with positive and negative NPI-dep scores were found with respect to age, sex, years of education, and cognitive function. Compared with patients with negative NPI-dep scores, patients with NPI-dep scores ≥1 showed significant hypoperfusion in the left middle frontal region. Our results indicate that the dorsolateral prefrontal area is significantly involved in the pathogenesis of depressive symptoms in AD patients being treated with AChEI. The area on the left side especially may be closely related to the depressive symptoms evaluated using the NPI.

KW - Acetylcholine esterase inhibitor (AChEI)

KW - Alzheimer׳s disease

KW - Depression

KW - Neuropsychiatric inventory (NPI)

KW - Regional cerebral blood flow (rCBF)

UR - http://www.scopus.com/inward/record.url?scp=84935513097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84935513097&partnerID=8YFLogxK

U2 - 10.1016/j.pscychresns.2014.10.008

DO - 10.1016/j.pscychresns.2014.10.008

M3 - Article

C2 - 25453992

AN - SCOPUS:84935513097

VL - 224

SP - 319

EP - 323

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 3

ER -